Eli Lilly and Company vs Novo Nordisk A/S: Strategic Comparison
Key Differences at a Glance
| Field | Eli Lilly and Company | Novo Nordisk A/S |
|---|---|---|
| Revenue | $65.2B | $46.0B |
| Founded | 1876 | 1989 |
| Employees | 50,000 | 69,505 |
| Market Cap | $1.05T | $550.0B |
| Headquarters | United States | Denmark |
Quick Stats Comparison
| Metric | Eli Lilly and Company | Novo Nordisk A/S |
|---|---|---|
| Revenue | $65.2B | $46.0B |
| Founded | 1876 | 1989 |
| Headquarters | Indianapolis, Indiana | Bagsvaerd, Denmark |
| Market Cap | $1.05T | $550.0B |
| Employees | 50,000 | 69,505 |
Eli Lilly and Company Revenue vs Novo Nordisk A/S Revenue — Year by Year
| Year | Eli Lilly and Company | Novo Nordisk A/S | Leader |
|---|---|---|---|
| 2025 | $65.2B | $46.0B | Eli Lilly and Company |
| 2024 | $45.0B | $42.7B | Eli Lilly and Company |
| 2023 | $34.1B | $34.0B | Eli Lilly and Company |
| 2022 | $28.5B | N/A | Eli Lilly and Company |
| 2021 | $28.3B | N/A | Eli Lilly and Company |
Business Model Breakdown
Overview: Eli Lilly and Company vs Novo Nordisk A/S
This in-depth comparison examines Eli Lilly and Company and Novo Nordisk A/S across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Eli Lilly and Company on its own, evaluating Novo Nordisk A/S, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Eli Lilly and Company and Novo Nordisk A/S is widest.
On the headline numbers, Eli Lilly and Company reports annual revenue of $65.2B against $46.0B for Novo Nordisk A/S, while their respective market capitalizations stand at $1.05T and $550.0B. Eli Lilly and Company is headquartered in United States and Novo Nordisk A/S operates from Denmark, and those different home markets shape how each company competes.
Eli Lilly and Company: Lilly has transformed from a broad pharmaceutical company into one of the world's most valuable drugmakers because of its cardiometabolic portfolio and pipeline. The core question is how long demand, capacity, and patent protection can compound.
Novo Nordisk A/S: Novo Nordisk A/S is a public company listed on NYSE under ticker NVO. Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.
Business Models: How Eli Lilly and Company and Novo Nordisk A/S Make Money
Eli Lilly and Company and Novo Nordisk A/S pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Eli Lilly and Company and Novo Nordisk A/S.
Eli Lilly and Company business model: Eli Lilly makes money by discovering, developing, manufacturing, and selling branded prescription medicines. Revenue depends on approved therapies, patents, clinical outcomes, manufacturing capacity, payer access, and global regulatory approvals.
Novo Nordisk A/S business model: Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.
Competitive Advantage: Eli Lilly and Company vs Novo Nordisk A/S
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Eli Lilly and Company stack up against those of Novo Nordisk A/S.
Eli Lilly and Company competitive advantage: Lilly's advantage comes from high-value intellectual property, clinical-development execution, biologics manufacturing scale, commercial access, and a concentrated portfolio of medicines with large addressable markets.
Novo Nordisk A/S competitive advantage: Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.
Growth Strategy: Where Eli Lilly and Company and Novo Nordisk A/S Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Eli Lilly and Company and Novo Nordisk A/S each plan to expand from here.
Eli Lilly and Company growth strategy: Lilly is investing heavily in manufacturing capacity, next-generation obesity and diabetes drugs, oncology, immunology, neuroscience, and external collaborations to extend growth beyond the first tirzepatide wave.
Novo Nordisk A/S growth strategy: Novo Nordisk A/S's growth strategy centers on this advantage: Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.
Financial Picture: Eli Lilly and Company vs Novo Nordisk A/S
A closer look at the financial trajectory of Eli Lilly and Company and Novo Nordisk A/S rounds out the comparison.
Eli Lilly and Company: Lilly reported 2025 revenue of $65.179 billion and net income of $20.640 billion. Revenue rose sharply from $45.043 billion in 2024 as demand for Mounjaro and Zepbound expanded.
Novo Nordisk A/S: Novo Nordisk A/S reported FY2025 revenue of DKK 309.064B (about $46.0B) and net income of DKK 102.434B (about $15.2B).
Company-Specific SWOT Notes
Eli Lilly and Company
Lilly's tirzepatide franchise represents one of the most commercially successful pharmaceutical launches in history, with combined Mounjaro and Zepbound revenues of approximately $13.
With more than 50 active molecules in clinical development and approximately $9.
Despite a multi-billion-dollar manufacturing expansion program, Lilly's production capacity for tirzepatide and other injectable biologics has lagged the extraordinary demand generated by commercial launches, resulting in drug shortages that have frustrated pa
While tirzepatide's revenue contribution is a strength in the short term, the concentration of approximately 30 percent of Lilly's total revenues in a single molecule creates significant vulnerability to regulatory, safety, manufacturing, or competitive develo
The development of effective oral GLP-1 and incretin-based therapies represents perhaps the largest single commercial opportunity in pharmaceutical history, as an oral formulation would eliminate the injection barrier that limits the addressable market to pati
The Inflation Reduction Act's Medicare drug price negotiation program, which allows the Centers for Medicare and Medicaid Services to directly negotiate prices for high-expenditure drugs, represents a structural threat to Lilly's revenue model in the United St
Novo Nordisk A/S
Novo Nordisk has global scale, clinical depth, and manufacturing experience in diabetes and obesity GLP-1 medicines.
A large share of investor expectations depends on continued Ozempic and Wegovy growth.
Obesity care, cardiovascular outcomes, oral formulations, and broader metabolic indications can expand the addressable market.
Rival incretin drugs, compounding, payer restrictions, safety scrutiny, and supply constraints can pressure growth.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Eli Lilly and Company | Eli Lilly and Company reports the larger revenue base ($65.2B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Eli Lilly and Company | Founded in 1876 vs 1989. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Eli Lilly and Company | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | Novo Nordisk A/S | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Eli Lilly and Company | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Eli Lilly and Company reports the larger revenue base ($65.2B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1876 vs 1989. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Eli Lilly and Company or Novo Nordisk A/S?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Eli Lilly and Company vs Novo Nordisk A/S
Is Eli Lilly and Company better than Novo Nordisk A/S?
Verdict: Between Eli Lilly and Company and Novo Nordisk A/S, Eli Lilly and Company is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, Eli Lilly and Company comes out ahead in this Eli Lilly and Company vs Novo Nordisk A/S comparison.
Who earns more — Eli Lilly and Company or Novo Nordisk A/S?
Eli Lilly and Company earns more with $65.2B in annual revenue versus Novo Nordisk A/S's $46.0B. Eli Lilly and Company leads on total revenue based on latest verified figures.
Which company has higher revenue — Eli Lilly and Company or Novo Nordisk A/S?
Eli Lilly and Company reported $65.2B, while Novo Nordisk A/S reported $46.0B. The revenue leader is Eli Lilly and Company based on latest verified figures.
Eli Lilly and Company revenue vs Novo Nordisk A/S revenue — which is higher?
Eli Lilly and Company revenue: $65.2B. Novo Nordisk A/S revenue: $46.0B. Eli Lilly and Company has the larger revenue base of the two companies.
Sources & References
- SEC EDGAR: Eli Lilly and Company Annual Filings (10-K, 8-K)
- Eli Lilly and Company Corporate Website
- Eli Lilly and Company Annual Report 2025 - Revenue and Financial Data
- sec.gov
- data.sec.gov
- investor.lilly.com
- finance.yahoo.com
- Novo Nordisk A/S Corporate Website
- Novo Nordisk A/S Annual Report 2025 - Revenue and Financial Data
- sec.gov
- novonordisk.com